Related Experiment Videos
Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies
C B Powell1, D G Mutch, L S Massad
1Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110.
Abstract:
The efficacy of tumor necrosis factor alpha (TNF alpha) as an anticancer agent is limited. This limitation might be related to the expression of a protein-synthesis-dependent resistance mechanism that prevents the lysis of tumor cells by TNF alpha. To test this possibility eight randomly selected human cell lines, three derived from ovarian carcinomas and five derived from cervical carcinomas, were tested for their in vitro sensitivity to TNF alpha-mediated lysis. The results of this analysis showed that all eight cell lines are normally resistant to lysis by TNF alpha. However, in the presence of inhibitors of protein synthesis, seven of them showed a significant increase in TNF alpha-mediated lysis. Measurement of protein synthesis showed that there is a linear correlation between the level of inhibition of protein synthesis and the level of TNF alpha-mediated lysis. The fact that seven of eight randomly selected cell lines are resistant to TNF alpha because they express a protein-synthesis-dependent resistance mechanism suggests that this mechanism of resistance may be common among gynecological cancers. The results also suggest that a therapy involving TNF alpha and inhibitors of protein synthesis might be useful for the treatment of gynecological malignancies.
Insights
Tumor necrosis factor alpha (TNF alpha) efficacy is limited by a protein-synthesis-dependent resistance in gynecological cancers. Inhibiting protein synthesis enhances TNF alpha
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Tumor necrosis factor alpha (TNF alpha) has potential as an anticancer agent.
- Its clinical efficacy is often limited by tumor cell resistance mechanisms.
- A protein-synthesis-dependent resistance may prevent TNF alpha-mediated tumor cell lysis.
Purpose of the Study:
- To investigate the sensitivity of gynecological cancer cell lines to TNF alpha.
- To determine if protein synthesis inhibition can overcome TNF alpha resistance.
- To explore the potential of combination therapy with TNF alpha and protein synthesis inhibitors.
Main Methods:
- In vitro testing of eight human gynecological cancer cell lines (3 ovarian, 5 cervical) for TNF alpha-mediated lysis.
- Assessment of TNF alpha sensitivity in the presence of protein synthesis inhibitors.
- Correlation analysis between the level of protein synthesis inhibition and TNF alpha-mediated lysis.
Main Results:
- All eight tested cell lines exhibited inherent resistance to TNF alpha-mediated lysis.
- Inhibition of protein synthesis significantly increased TNF alpha-mediated lysis in seven of the eight cell lines.
- A linear correlation was observed between the degree of protein synthesis inhibition and the extent of TNF alpha-mediated lysis.
Conclusions:
- A protein-synthesis-dependent resistance mechanism is likely common in gynecological cancers, limiting TNF alpha efficacy.
- Combination therapy using TNF alpha and protein synthesis inhibitors may represent a promising strategy for treating gynecological malignancies.
- Further research into this combination therapy is warranted for clinical application.